
ATTO Stock Forecast & Price Target
ATTO Analyst Ratings
Bulls say
Attovia Therapeutics is taking a unique approach to biotechnology research and development by utilizing its ATTOBODY platform to design and develop optimized biologics targeting validated targets in the immune-mediated diseases space. This approach has been validated by the success of its lead product, ATTO-1310, which has shown promising early data and a clear roadmap for success in the treatment of high-itch indications like chronic pruritus and atopic dermatitis. Additionally, Attovia's pipeline includes ATTO-1091, a trispecific drug targeting three high-validated inflammatory bowel disease targets, which has shown promise in preclinical studies and has the potential to be a best-in-disease therapy. With a strong R&D engine and potential for both revenue and market growth, Attovia Therapeutics Inc represents a promising investment opportunity with significant upside potential.
Bears say
Attovia Therapeutics is a clinical stage biotechnology company with a focus on developing novel biologics targeting immune-mediated diseases. However, the company's limited pipeline and potential competition in the space pose risks for future commercialization and revenue generation. Additionally, concerns about the efficacy and dosing frequency of its lead asset, ATTO-1310, may lead to a downside revision in estimates, resulting in a fair value of $11.
This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ATTO Analyst Forecast & Price Prediction
Start investing in ATTO
Order type
Buy in
Order amount
Est. shares
0 shares